Vascular access system maker Avenu Medical said last Friday it won a HCPCS C-Code from the Centers for Medicare and Medicaid Services for its Ellipsys dialysis device and the endoAVF procedure.
The San Juan Capistrano, Calif.-based company’s Ellipsys vascular access system device is designed for use with end-stage renal disease patients who require hemodialysis. The system, which can be used under local or regional anesthesia, uses an ultrasound-guided catheter that delivers a small amount of thermal energy to fuse a permanent anastomosis between the vein and artery to create an AVF.
The newly granted HCPCS reimbursement C-Code was granted in a final ruling from CMS, and will go into effect January 1.
“What a rewarding experience to receive a C-code right as we are presenting our technology at CiDA, one of the premiere dialysis access medical conferences in the world. We are grateful to CMS for its foresight in creating a fair and reasonable reimbursement scenario. This will make vascular access for hemodialysis more widely available to the underserved ESRD patient population nationwide, signaling a significant quality-of-life improvement for patients and their loved ones,” Avenu co-founder & marketing VP Ed Chang said in a prepared statement.
In June, Avenu Medical said that it won FDA de novo clearance for its Ellipsys vascular access system.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.